{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-014848","form_type":"8-K","ticker":"PVCT","cik":"0000315545","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2024-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.528062+00:00","generated_at":"2026-06-03T22:28:21.173369+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Provectus appoints Pershing as CEO and Rodrigues as President effective April 16","bullets":["Ed Pershing appointed CEO effective April 16; will continue as Board Chairman; salary $240,000/year.","Dominic Rodrigues appointed President effective April 16; will continue as Vice Chairman; salary $240,000/year.","Both executives have employment agreements with change-in-control severance provisions.","Rodrigues' prior independent contractor agreement (March 2024) terminated; he had served as chief operating consultant.","Press release outlines 2024 focus: pancreatic cancer clinical program, capital raising at fair valuation, and enhanced investor outreach."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-014848","json":"https://secwatch.observer/filing/0001493152-24-014848.json","markdown":"https://secwatch.observer/filing/0001493152-24-014848.md","text":"https://secwatch.observer/filing/0001493152-24-014848.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/315545/000149315224014848/0001493152-24-014848-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/315545/000149315224014848/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:28:21.173369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9aa90322c9","claim":"Dominic Rodrigues was appointed as President at PROVECTUS BIOPHARMACEUTICALS, INC..","evidence_excerpt":"appointed Dominic Rodrigues as the Company’s President effective April 16, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/315545/000149315224014848/0001493152-24-014848-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"9d03046c81","claim":"Ed Pershing was appointed as Chief Executive Officer at PROVECTUS BIOPHARMACEUTICALS, INC..","evidence_excerpt":"appointed Ed Pershing as the Company’s Chief Executive Officer effective April 16, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/315545/000149315224014848/0001493152-24-014848-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}